Clinical Trials Logo

Prodromal Schizophrenia clinical trials

View clinical trials related to Prodromal Schizophrenia.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT06190483 Completed - Clinical trials for Prodromal Schizophrenia

Investigating the Role of Diazepam on Brain Function and Chemistry in Psychosis Risk

BENZOGAP
Start date: July 24, 2019
Phase: N/A
Study type: Interventional

This study will investigate whether a single dose of diazepam (5mg) compared to placebo can modulate brain chemistry (GABA/glutamate levels) and function (blood flow, neural response and connectivity during tasks and at-rest) in 24 individuals at clinical high-risk for psychosis.

NCT ID: NCT03447548 Completed - Clinical trials for Prodromal Schizophrenia

Neurofeedback Training for High Risk Psychosis

Start date: March 1, 2018
Phase: N/A
Study type: Interventional

Young people who are at great risk for developing psychosis have cognitive deficits which are strongly related to functioning in the community. This study looks to target a specific cognitive skill called processing speed to see if improving the ability to process information in a timely manner will improve social function in adolescents and young adults at risk for developing schizophrenia. Half will receive neurofeedback cognitive training targeting processing speed while the other half will receive an active control.

NCT ID: NCT01619319 Completed - Clinical trials for Prodromal Schizophrenia

Effects of Cognitive Remediation on Cognition in Young People at Clinical High Risk of Psychosis

Start date: July 2010
Phase: N/A
Study type: Interventional

Onset of psychotic disorders such as schizophrenia, typically occurs during late adolescence or early adulthood often resulting in chronic social and occupational disability. Deficits in cognition and functional outcome often precede the onset of full-blown psychosis although to a lesser degree than observed in schizophrenia. Recent progress in risk identification methodology has enabled reliable detection of persons who appear to be putatively prodromal for psychosis, that is, at clinical high risk (CHR) of developing a psychotic disorder. Since these CHR individuals already evidence cognitive deficits, which increase around the time of conversion, cognition is an excellent treatment target. Furthermore, there is clear evidence, in schizophrenia and in CHR samples, that deficits in cognition are related to poor functional outcome. Thus, treatments targeting cognition may consequently improve functional outcome. The primary aim of the project is to reduce cognitive deterioration and improve cognition among youths at CHR using cognitive remediation and to test the effectiveness of a new cognitive remediation program, the Brain Fitness program, in improving cognition of CHR individuals. A control treatment consisting of video games (VG) will be used. The primary hypothesis is that the BF group will have improved cognition at the end of treatment and 12 months post baseline compared to the VG group. A secondary hypothesis is that improved cognition will be associated with improved functioning. This is a longitudinal, single blind, placebo controlled pilot trial of cognitive remediation in 36 CHR persons. Participants will be randomised to either the BF or VG program, which will be administered over a period of 3 months. Assessments will occur at baseline, post treatment (3 months) and at 12 months after baseline. All subjects will be recruited in year 1 of the project and treatment will be completed by 15 months. The 40 hours of training will occur 4 days a week, for an hour each day, over a period of 10 -12 weeks.

NCT ID: NCT01597141 Completed - Psychotic Disorders Clinical Trials

Psychosis: Early Detection, Intervention and Prevention

EDIP
Start date: May 2003
Phase: N/A
Study type: Interventional

The primary aim of this application is to conduct a randomized, controlled clinical trial of a specialized mental health service delivery system specifically developed for prodromal psychotic disorders. The intervention is Family-aided Assertive Community Treatment (FACT). The goal of the treatment is prevention of psychosis and disability. This study will assess experimentally the clinical effectiveness of this new type of mental health service. Other domains of outcome include cognitive dysfunction and functional disability.

NCT ID: NCT01269710 Completed - Schizophrenia Clinical Trials

Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study

SATIETY
Start date: October 2009
Phase: N/A
Study type: Observational

The purpose of this study is to get a better understanding of the side effect burden and identify predictors of psychotic, mood and aggressive disorders in children and adolescents. The study's primary aim is to identify genetic risk factors for weight gain and metabolic abnormalities.

NCT ID: NCT00169988 Completed - Psychotic Disorders Clinical Trials

Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative Symptoms

Start date: March 2004
Phase: N/A
Study type: Interventional

The Recognition and Prevention (RAP) Program is conducting a research study comparing an antidepressant, sertraline, alone versus in combination with a second-generation antipsychotic, risperidone, to evaluate their ability to reduce unusual thoughts, suspiciousness and other unusual experiences, to improve reasoning ability, memory, attention and social skills in adolescents.